Beta-site APP-cleaving enzyme 1 (BACE1, also called Memapsin 2) has long been known to be a primary enzyme responsible for processing APP into Aβ and has been a leading target for AD therapeutic intervention [13]. The gene discussed is BACE1; the disease is Alzheimer disease.